As an oncologist with over 15 years of experience treating breast cancer patients, I've witnessed firsthand the challenges faced by those with advanced hormone receptor-positive (HR+) and HER2-negative (HER2-) disease. Endocrine therapies have long been a cornerstone of treatment, but resistance often develops, leaving patients with limited options. That's why the recent approval of Entinostat...